بحث بيانات أعضاء هيئة التدريس - جامعة الزقازيق

/ بحث بيانات أعضاء هيئة التدريس - جامعة الزقازيق

لايوجد

الموقع الشخصى

هبه فكرى عبد المجيد طه ابراهيم

الكلية الطب - القسم طب الأورام

الدرجات العلمية

بكالوريوس فى الطب والجراحه, -جامعة الزقازيق [1999]
ماجستير فى الباطنه العامه, -جامعة الزقازيق [2005]
(تقييم ال بى ـ جليكوبروتين فى مرضى أورام الغدد الليمفاوية الغير هودجيكن المنتكس والمقاوم للعلاج والأستجابة للعلاج ببروتوكول (أم - أى - ان - اى ))
دكتوراه فى الباطنه العامه, -جامعة الزقازيق [2012]

الحالة الوظيفية الحالية :

قائم بالعمل

التدرج الوظيفى الأكاديمى

معيد : 3/3/2005
مدرس مساعد : 15/3/2006
مدرس : 30/10/2012
أستاذ مساعد : 31/3/2020
أستاذ : 29/4/2025

الأبحاث العلمية

1 - Combined Ezrin overexpression and E-cadherin downregulation as predictors of invasiveness, higher incidence of metastases, progression and poor prognosis in patients with cervical cancer (1439).

2 - The Value of FAK and SLUG Expression in Patients with Breast Carcinoma and Relation of Their Expression to Clinicopathological and Prognostic Parameters (1439).

3 - SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell carcinoma (cc-RCC): Clinicopathological and prognostic significance (1440).

4 - Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study. (1440).

5 - The diagnostic role of Arginase1, MOC31, and CDX2 in the differentiation of hepatocellular carcinoma, cholangiocarcinoma and metastatic colonic carcinoma of the liver (1441).

6 - Concordance between ER, PR, HER-2 neu Receptors Before and after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (1441).

7 - Clinical, pathological and prognostic implications of USP22, SIRT1 and Ecadherin expression in papillary thyroid cancer (PTC) and adjacent non-neoplastic tissue (1440).

8 - Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions (1440).

9 - Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions (1440).

10 - Prognostic Significances of NEDD-9 and FOXL-1 Expression in Intestinal Type Gastric Carcinoma: an Immunohistochemical Study. (1442).

11 - Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study (1442).

12 - Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years (1444).

13 - Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy (1443).

14 - Baseline Peripheral Blood Monocytosis Carries Worse Leukemia-Free Survival in Acute Myeloid Leukemia Without Monocytic Differentiation (1444).

15 - Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte, and platelets score. (1444).

16 - Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. (1444).

17 - Prognostic Value of Time Interval Between Induction Chemotherapy and Autologous Stem Cell Transplantation among Multiple Myeloma Patients (1446).

18 - Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women (1442).

19 - Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients (1443).

20 - Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols (1444).

21 - The prognostic Value of Cancer Stem Cell Marker, Cluster of Differentiation 133 Expression in Stage III Colorectal Carcinoma (1444).

22 - Impact of Ki 67 and Progesterone receptor status on the outcome of metastatic breast cancer patients treated with cyclin dependant kinase inhibitors (1446).

المجالات البحثية